Cancer Immunology Research · 2015 · 20 citations · 42 references
Life SciencesImmunologyOncologyImmunotherapySignal TransductionTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCombination ImmunotherapyCytokines In Tumor ImmunityImmunotherapy For Solid TumorsT Cell Responses To TumorsAntibodiesCd4+ Tumor-infiltrating LymphocytesCd8 Positive T CellsCd8+ Tumor-infiltrating LymphocytesCombination TherapyStat3 SignalingTransforming Growth Factor Beta-mediated Immune SuppressionTumor Microenvironment Effects
In preclinical tumor models, αOX40 therapy is often successful at treating small tumors, but is less effective once the tumors become large. For a tumor immunotherapy to be successful to cure large tumors, it will most likely require not only an agonist to boost effector T-cell function but also inhibitors of T-cell suppression. In this study, we show that combining αOX40 antibodies with an inhibitor of the TGFβ receptor (SM16) synergizes to elicit complete regression of large established MCA205 and CT26 tumors. Evaluation of tumor-infiltrating T cells showed that SM16/αOX40 dual therapy resulted in an increase in proliferating granzyme B(+) CD8 T cells, which produced higher levels of IFNγ, compared with treatment with either agent alone. We also found that the dual treatment increased pSTAT3 expression in both CD4 and CD8 T cells isolated from tumors. Because others have published that STAT3 signaling is detrimental to T-cell function within the tumor microenvironment, we explored whether deletion of STAT3 in OX40-expressing cells would affect this potent combination therapy. Surprisingly, we found that deletion of STAT3 in OX40-expressing cells decreased the efficacy of this combination therapy, showing that the full therapeutic potential of this treatment depends on STAT3 signaling, most likely in the T cells of tumor-bearing mice.
42
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Vijay Shankaran, Hiroaki Ikeda, Allen T. Bruce et al. · Nature · 2001 · 2.8K citations
Life Sciences, Immunology, Oncology +12
A2A adenosine receptor protects tumors from antitumor T cells
Akio Ohta, Elieser Gorelik, Simon J. Prasad et al. · Proceedings of the National Academy of Sciences · 2006 · 1K citations
Medicine, Immunology, Oncology +16